62 related articles for article (PubMed ID: 17060971)
1. EGF receptors as a target for cancer therapy.
Mendelsohn J
Trans Am Clin Climatol Assoc; 2004; 115():249-53; discussion 253-4. PubMed ID: 17060971
[No Abstract] [Full Text] [Related]
2. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy.
Huang SM; Li J; Harari PM
Cancer Chemother Biol Response Modif; 2001; 19():339-52. PubMed ID: 11686022
[No Abstract] [Full Text] [Related]
3. [Targeting therapy directed against growth factor receptor].
Ueda M; Abe O; Shimizu N
Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1436-42. PubMed ID: 1871365
[No Abstract] [Full Text] [Related]
4. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice.
Baradaran B; Hosseini AZ; Majidi J; Farajnia S; Barar J; Saraf ZH; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(1-2):11-6. PubMed ID: 19478394
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of EGFR and VEGF inhibition.
Pander J; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885
[TBL] [Abstract][Full Text] [Related]
7. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for colorectal cancer.
Hwang J; Marshall JL
Curr Opin Investig Drugs; 2006 Dec; 7(12):1062-6. PubMed ID: 17209523
[TBL] [Abstract][Full Text] [Related]
9. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
10. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
Youssoufian H; Hicklin DJ; Rowinsky EK
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5544s-5548s. PubMed ID: 17875787
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV.
Ho DT; Wykoff-Clary S; Gross CS; Schneider D; Jin F; Kretschmer PJ; Hermiston TW
Cancer Gene Ther; 2009 Feb; 16(2):184-94. PubMed ID: 18758433
[TBL] [Abstract][Full Text] [Related]
12. New agents in development for breast cancer.
Gao XP; Liu F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor receptor as a target for therapy.
Harris AL
Cancer Cells; 1990 Oct; 2(10):321-3. PubMed ID: 2282249
[No Abstract] [Full Text] [Related]
14. [Gene delivery by immunogene and its application to cancer gene therapy].
Gamou S; Chen J; Takayanagi A; Shimizu N
Tanpakushitsu Kakusan Koso; 1995 Dec; 40(17):2562-9. PubMed ID: 8584701
[No Abstract] [Full Text] [Related]
15. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
Surguladze D; Deevi D; Claros N; Corcoran E; Wang S; Plym MJ; Wu Y; Doody J; Mauro DJ; Witte L; Busam KJ; Pytowski B; Rodeck U; Tonra JR
Cancer Res; 2009 Jul; 69(14):5643-7. PubMed ID: 19584274
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
Wheatley-Price P; Shepherd FA
Curr Opin Oncol; 2008 Mar; 20(2):162-75. PubMed ID: 18300766
[TBL] [Abstract][Full Text] [Related]
17. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?
Dancey JE
J Clin Oncol; 2004 Aug; 22(15):2975-7. PubMed ID: 15210735
[No Abstract] [Full Text] [Related]
19. [Esophageal cancer].
Satoh T; Kudo T; Sakai D; Haraguchi N; Ishii H; Doki Y; Mori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():434-7. PubMed ID: 23513879
[No Abstract] [Full Text] [Related]
20. [Spring meeting of the French Federation of Digestive Oncology, co-organized with the French Cancer Society. Clermont-Ferrand, June 22, 2007].
Auvray H
Bull Cancer; 2008 Jan; 95(1):166-71. PubMed ID: 18230584
[No Abstract] [Full Text] [Related]
[Next] [New Search]
